That brings us to the term ‘semi-exclusive’ within Tuesday’s release. Biocurex, for obvious reasons, is loath to grant exclusivity to any one company. Top-tier companies such as Abbott historically tend to want exclusivity. The fact that Abbott entered into a semi-exclusive arrangement, leaving Biocurex the right to enter into licensing arrangements with other companies, we believe, evidences the potential it sees in the technology and further enforces RECAF’s™ viability.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.